Richard Van Krieken

TitlePostdoctoral Scholar - Research Associate
InstitutionUniversity of Southern California
DepartmentCancer Center
Address1441 Eastlake Avenue
Health Sciences Campus
Los Angeles CA 90033
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Van Krieken R, Marway M, Parthasarathy P, Mehta N, Ingram AJ, Gao B, Krepinsky JC. Inhibition of SREBP with fatostatin does not attenuate early diabetic nephropathy in male mice. Endocrinology. 2018 Feb 05. PMID: 29420703.
      View in: PubMed
    2. Van Krieken R, Krepinsky JC. Caveolin-1 in the Pathogenesis of Diabetic Nephropathy: Potential Therapeutic Target? Curr Diab Rep. 2017 03; 17(3):19. PMID: 28283950.
      View in: PubMed
    3. Van Krieken R, Chen G, Gao B, Read J, Al Saleh HA, Li R, Al-Nedawi K, Krepinsky JC. Sterol Regulatory Element Binding Protein (SREBP)-1 is a novel regulator of the Transforming Growth Factor (TGF)-ß receptor I (TßRI) through exosomal secretion. Cell Signal. 2017 01; 29:158-167. PMID: 27826032.
      View in: PubMed
    4. Chen G, Wang T, Uttarwar L, vanKrieken R, Li R, Chen X, Gao B, Ghayur A, Margetts P, Krepinsky JC. SREBP-1 is a novel mediator of TGFß1 signaling in mesangial cells. J Mol Cell Biol. 2014 Dec; 6(6):516-30. PMID: 25348957.
      View in: PubMed
    5. Ramadeen A, Connelly KA, Leong-Poi H, Hu X, Fujii H, Van Krieken R, Laurent G, Holub BJ, Bazinet RP, Dorian P. N-3 polyunsaturated fatty acid supplementation does not reduce vulnerability to atrial fibrillation in remodeling atria. Heart Rhythm. 2012 Jul; 9(7):1115-1122.e4. PMID: 22342864.
      View in: PubMed